Enlivex Therapeutics Ltd.
ENLV
$1.00
-$0.01-0.99%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 937.00K | 954.00K | 2.06M | 771.00K | 987.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.08M | 3.50M | 5.48M | 3.12M | 2.99M |
| Operating Income | -3.08M | -3.50M | -5.48M | -3.12M | -2.99M |
| Income Before Tax | -1.87M | -3.45M | -5.18M | -2.60M | -3.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.87M | -3.45M | -5.18M | -2.60M | -3.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.87M | -3.45M | -5.18M | -2.60M | -3.10M |
| EBIT | -3.08M | -3.50M | -5.48M | -3.12M | -2.99M |
| EBITDA | -2.99M | -3.41M | -5.45M | -2.96M | -2.83M |
| EPS Basic | -0.08 | -0.15 | -0.23 | -0.12 | -0.16 |
| Normalized Basic EPS | -0.05 | -0.09 | -0.12 | -0.08 | -0.10 |
| EPS Diluted | -0.08 | -0.15 | -0.23 | -0.12 | -0.16 |
| Normalized Diluted EPS | -0.05 | -0.09 | -0.12 | -0.08 | -0.10 |
| Average Basic Shares Outstanding | 23.86M | 23.76M | 22.49M | 21.28M | 19.55M |
| Average Diluted Shares Outstanding | 23.86M | 23.76M | 22.49M | 21.28M | 19.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |